The method and results of the review of the contraindication Hypertension have been published in the international scientific journal Frontiers in Pharmacology. The article by Özokcu et al. 2024 was written by the KNMP and Health Base, in collaboration with experts in the field of hypertension. The publication in this scientific journal endorses the working method of Health Base and the KNMP for developing medication monitoring for contraindications. The full article in English can be read here.
The Medicines Information Center (GIC) of the KNMP and Health Base jointly revised the medication monitoring advice for the contraindication of Hypertension in 2021. The review took place on the basis of a predetermined assessment framework, in which, among other things, the clinically relevant outcome measures were described. Following the revision, advice is only shown for corticosteroids and danazol. For certain medicines for which the package leaflet or SmPC does warn about hypertension, the Contraindications working group of the KNMP and Health Base decided that there was no clinically relevant increase or decrease in blood pressure. Examples of this are antidepressants and hormonal contraceptives. With other medicines, blood pressure monitoring takes place on a protocol basis during treatment, or the medicine is only used for a short period of time. A medication monitoring signal for hypertension is therefore unnecessary.
The medication monitoring advice is available via Pharmabase and G-Standaard. The complete background information and assessment reports can be consulted via Medication Monitoring Comments and the KNMP Knowledge Base.
Tags: Publication revision contraindication Hypertension international journal
